John F. Manzello President & CEO 369 Lexington Avenue, 17 th Floor New York, NY 10017 jmanzello@promosome.com (508

1. Promosome Corporate Introduction John F. ManzelloPresident & CEO 369 Lexington Avenue, 17th Floor New York, NY 10017 jmanzello@promosome.com (508) 845-2255

2. Promosome LLC Promosome is a New York City based biotechnology company with facilities in La Jolla CA and a research relationship with The Scripps Research Institute. Founded in 2003 by the highly regarded life sciences team of John R. Costantino and William J. Gedale, to commercialize the discoveries of Nobel Laureate Dr. Gerald Edelman, his colleague Dr. Vincent Mauro and other researchers at The Scripps Research Institute in La Jolla, CA. The expertise and continued focus of this research team at Scripps is in areas of Gene Regulation and Protein Expression through Translation Initiation. Through this expertise the Scripps team has developed a world leading understanding of mRNA translation and has established several commercially applicable technologies with an emphasis on serving the therapeutic and industrial bioproduction space.

3. Promosome LLC & The Scripps Research Institute • The Scripps Partnership: • Promosome and TSRI are currently completing the third consecutive 2 Year Research Funding and Option (RFO) Agreement extension specific to the laboratories of Drs. Edelman and Mauro. Promosome and TSRI anticipate the relationship to continue into a fourth consecutive extension. • Through the RFO, Promosome has exclusive, sole, worldwide rights to license any and all translational discoveries related to bioproduction, DNA Vaccines and other applications developed under the funding arrangement. • Scripps holds a 10 % founder’s equity interest, subject to normal dilution – No Future Royalties.

4. Promosome LLC Promosome is commercially leveraging the Scripps based knowledge through three significant bioproduction solutions relating to enhanced protein expression and mammalian cell line development. TEEs Translational Enhancing Elements RESCUE Reengineering mRNA Primary Structure for Enhanced Protein Production Site Specific Chromosomal Integration - Landing Pad

5. TSRI / Promosome Invention Disclosure, Patent & License Process 1. Promosome funds the laboratory and the specific research. (Through 2011) 2. Researchers discover technologies and submit as inventions to TSRI. 3. TSRI extends an Option to License to Promosome of said invention. 4. TSRI & Promosome jointly develop the patent strategy. 5. Patent is filed accordingly. 6. Promosome executes License Option. 7. Promosome initiates commercialization & sub-license strategies.

6. TSRI / Promosome Invention Disclosure, Patent & License Process 1. Promosome funds the laboratory and the specific research. (Through 2011) 2. Researchers discover technologies and submit as inventions to TSRI. 3. TSRI extends an Option to License to Promosome of said invention. 4. TSRI & Promosome jointly develop the patent strategy. 5. Patent is filed accordingly. 6. Promosome executes License Option. 7. Promosome initiates commercialization & sub-license strategies. TEE , RESCUE & Landing Pad Technologies

7. Technology License • TEEs Translational Enhancer Elements • Provisional Patent Application - December 2007 • License to Promosome – January 2008 • Commercial Launch – January 2008 • RESCUE Reengineering of mRNA Primary Structure for Enhanced Protein Expression • Provisional Patent Application – February 24, 2009 • Licensed to Promosome – July 2009 • PCT Patent Application - February 24, 2010 • Launch for Commercialization / Sublicense – January 2011 • Landing Pad Site Specific Chromosomal Integration (mammalian cells) • Invention released to TSRI - August 2009 • TSRI Option to License to Promosome - August 2009 • Provisional Patent Application Anticipated – March 2010 • Licensed to Promosome – April 2010 • Launch for Commercialization / Sublicense – April 2011